BackMineralys Therapeutics Overview

Mineralys Therapeutics Accounts Payable

Mineralys Therapeutics's accounts payable is $1.1M.

Get informed when a big investor buys or sells

+ Follow
Accounts Payable
$1.07M
66.31% YoYΔ $-2.10M vs prior year quarter

Peer trimmed avg / median

Loading

Mineralys Therapeutics Accounts Payable History

Loading

Mineralys Therapeutics vs. peers: Accounts Payable Comparison

Loading

Mineralys Therapeutics Accounts Payable Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Mineralys Therapeutics (MLYS) FAQ

As of the most recent data (June 2026), MLYS shows a accounts payable of $1.1M. That compares with $3.2M in the prior-year period — down 66.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, MLYS's accounts payable is now $1.1M (was $3.2M) — a 66.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Mineralys Therapeutics is outperforming or lagging.

Tracking MLYS's accounts payable over time shows whether Mineralys Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $1.1M That compares with $3.2M in the prior-year period — down 66.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this accounts payable page, Stockcircle has Mineralys Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect accounts payable (currently $1.1M) with ownership activity and broader fundamentals.